{"name":"Istari Oncology, Inc.","slug":"istari-oncology-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Anti-PD-1 Checkpoint Inhibitor","genericName":"Anti-PD-1 Checkpoint Inhibitor","slug":"anti-pd-1-checkpoint-inhibitor","indication":"Non-small cell lung cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Lerapolturev","genericName":"Lerapolturev","slug":"lerapolturev","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Anti-PD-1 Checkpoint Inhibitor","genericName":"Anti-PD-1 Checkpoint Inhibitor","slug":"anti-pd-1-checkpoint-inhibitor","phase":"phase_2","mechanism":"Inhibits PD-1 receptor","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Lerapolturev","genericName":"Lerapolturev","slug":"lerapolturev","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxPVmY3bzdxV016RkdZNW9CR0xZcTZiYjRKM3g3SWdaR0R1ejJuNzlqeU42cno2UllMbHR1VFB6Y0kxWDJpYVBTU1VhOU1rNzdEcmpDNEc2ZGNLcmlxRnNGb09UQy11MzlDZkducEtKYkZ6dFhxU1d3NEd4QkpNdUFDQUUtNDdjMmVodFVfWmUtRmkyM2M0bDMtNkNVeEVyOWNOcFkySkRRV3BRZ0docXhnWDY2cjVTY0plRHUwR2dpM19RQmJmbDlUSVRNWDFjbWhiYzZ2cVRrcVhiQS1vSW1XajgtOVBoNUVtY2UxZjJWcFpXMGFUMDVNRk9wdTQyakhtYmFxZUtLSjlkUzBod2dETk1uMzc1YjRKRWpMZlc1bkJoeW1VeE91ODFUem1zSGo2R3h5MWs4ZGZuRkJWZF9QLUs4MDhxLXhRNklJTFpMYmstUmtDNkVF?oc=5","date":"2026-03-30","type":"pipeline","source":"GlobeNewswire","summary":"Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow - GlobeNewswire","headline":"Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"bolsamania.com","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - bolsamania.com","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQTWE5bUN3RXk0aDJSUmFRSVFJYkdYemFGc21xY2VKYWZvYzBGZUtfejQwdXdsaWc4NVhYRHBhaWt6SDJILTJwTi1aamRqeHZkUkhMNThnbzViU3FFelNuRktzYWpjOHNMNHJkRzYyTjdmekh1U2paeVNfa25hOHNCeGVvY3U2OURreXdhMHVwclNKM1ZWR2k2Q1BLRHd2QTdxcXNQWkRsdW5fd3dfOGkyUXpvZk9JRGNwWV9HNjNnMTlObWlDZU1WV25EN29XMGN6UTJQUzV2XzloQ2FuX203b1RDVGotdGpYb3FnOFN3M25jR25ITkRmd2cxY3o3dGx1cFN5WFJFb0xXdFQ0OEU3VFZsZUxCTXdoYjVvVFh0TUxRQWpuQXVONU9YQURJWlJF?oc=5","date":"2025-09-23","type":"trial","source":"GlobeNewswire","summary":"TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ - GlobeNewswire","headline":"TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPTFJoX0hUV2FlQm1UNGFrVGNGNHQ4blpES3lULTcxTUJBYzVxbS1JMS1XdkNWNlZTVTJiQ041Z3ZPd1RSMU9LcGZLaFBfRVZuOV9uWC05dWhhR1VGUU1fNFNwNHozTzNvY1JaRzctNm82Tk9DaXk2SmJKUmZMQ09aRFNDa1pQNWxCYWhiNU1EcjQ?oc=5","date":"2025-07-22","type":"pipeline","source":"Yahoo Finance","summary":"Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - Yahoo Finance","headline":"Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPTmVHeWZWbDcwMFFqZUZzZlNaZFpYdGNCbldZczFISUNLYXNwVTB5M24wLXdleGNaMDZXWE4tc3BiSjZfb1N1Y2VtT0Rxdlp3S3ZGOHhzOG9QNG1wN1VHVmx3bUk3QVNPUncta2thZUtSOUpZTmtUb3ZnVlpEV2V0c0k4cl9maGFVbVdPc291V1hRQjVGSTBOd3NxYlJwMlpHc09fTzFDV0dsZ1ZmVHd2Rl84S0dyYVpYZ1gtYlZ1RXlmbUwxa3E4anJuVjhkTHBJSW8ydGlyRk9EMXZZbWtVaXBjbWVuSHVrZ1lxbDViTC0wa0FwZ2RsekRibDhydUk4TTl4MUdMN1ViMWctWk5pVnJJZ0RhZTR5?oc=5","date":"2024-11-25","type":"pipeline","source":"GlobeNewswire","summary":"Neuroendocrine Tumors Market to Showcase Rapid Growth - GlobeNewswire","headline":"Neuroendocrine Tumors Market to Showcase Rapid Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxQeVhsa2xJM0s1LVRQQ2pJVEFhcmNfQ3NUQV9URkJwRlJpUDJEdTFLaFIwUS03ckd0bU9tcmFyRFZQdXFSMUhZVmV2RlE5aVR6SkVoZGt4dVFwTmZtSGxmcThqYmxwbm13VnduZXR5T0t2WkF1dnN1RXpsYTRoN0ZBbWpwNDFybTJ6ejZiMHd0SU80SXk3V0xUSm15cTRRbGlRMllGQkdSdVdmVkJmdFI5cGdJR3RvbVZEME5adTNWWklldk5RQ0FHOXkwTVNBZVRkMUZZeDBMYmZEQ211S2tGSC1SelZWMUx2NHFrLXV5d1pablJXa2hfcGg0eUtGVGlLT0FyaGtqSWRHLW10NzZ3RDZYaDFkb1Nwam50ZWFjaDJHRkVDOTRFY1B2M09tVTJ3VW5PQ1RJWjRQeGpGV1FZNjUxU2JyVEhmRjVZa1Jiek9kb2hnN3lmVWhGdw?oc=5","date":"2023-03-22","type":"pipeline","source":"GlobeNewswire","summary":"Brain Cancer Market Size to Propel With the Active - GlobeNewswire","headline":"Brain Cancer Market Size to Propel With the Active","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}